跳至主要内容
临床试验/NCT02047422
NCT02047422撤回不适用

A Prospective, Single-center, Randomized, Controlled, Open-label, Pilot Study to Compare the Effectiveness and Safety of DIuretics Add-On Strategy in Acute Decompensated Heart Failure Patients (DIOS II)

Yonsei University0 个研究点开始时间: 2014年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
撤回
主要终点
urine output change

研究概览

简要总结

To compare the effectiveness and safety of diuretics add-on strategy in chronic heart failure patients

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • dyspnea at rest or minimal activity
  • tachypnea (respiratory rate > 20/min) or rales or pulmonary edema on chest X-ray

排除标准

  • hospitalization for acute heart failure decompensation
  • cardiogenic shock (Systolic Blood Pressure < 80mmHg)
  • Need or plan for renal replacement therapy (dialysis, kidney transplant)
  • serum creatine level > 2.5mg/dl
  • serum potassium (K+) > 5.5mg/dl
  • Age > 80 years old or poor compliance patients
  • allergy, adverse drug reaction, hypersensitivity to any kinds of diuretics
  • life expectancy < 6 months (e.g. metastatic malignancy, liver cirrhosis)
  • pregnancy or women at age of childbearing potential

研究组 & 干预措施

Add furosemide/no spironolactone

Experimental

干预措施: Furosemide (Drug)

Add metolazone/no spironolactone

Experimental

干预措施: metolazone (Drug)

Add furosemid/spironolactone

Experimental

干预措施: furosemid/spironolactone (Drug)

Add metolazone/spironolactone

Experimental

干预措施: metolazone/spironolactone (Drug)

结局指标

主要结局

urine output change

时间窗: from admission to Hospital Day (HOD)#4

efficacy of diuretics add-on therapy, urine output change

次要结局

  • serum creatinine change(from admission to HOD#4)

研究者

申办方类型
Other
责任方
Sponsor

相似试验